-
04-05-2016, 09:51 PM
#131
Originally Posted by Joshuatree
Took profits today.Hoping to have another go a few months down the track. Too much uncertainty, $3 mill cash burn for qtr , cap raising around the cnr?.Not shifting enough units.FDA approval would be a boost and sales to china could surprise.
-
23-05-2016, 10:41 PM
#132
Haven't checked right back.Is anyone in VLA Viralytics VLA?.Cancer, melanoma etc. Heres a few research reports Roth have a $3.84 target ,s/p 79c atm. A couple of friends hold.
Eye-Catching MITCI Data
Viralytics’ Cavatak Delivers Benefits In Combination With Checkpoint Inhibitors
CAVATAK Plugging Away on All Fronts; Nice CALM and MITCI Updates
MITCI Results Show Promise
-
24-05-2016, 02:15 PM
#133
Junior Member
I've been in for about a year - taking a small position on the first leg up from memory and adding a few more in the SPP. It was very much a punt though since I'm not familiar with the field and have recently re-balanced. That aside, they have a solid cash position, the recent news results/news flow seems to have been well-received and you have to love the price targets floating round
.
-
26-07-2016, 07:28 PM
#134
Originally Posted by DarkHorse
Indeed they are in early trials and unprofitable, albeit apparently sitting on $18m cash. They used to be a kind of biotech incubator with fingers in several pies. Over past year they've ditched other divisions and put sole focus on treatment for Wet AMD, the leading cause of blindness in the western world, with a potential market of $5 billion in the US and $10b worldwide. Hence the recent 'rebranding' to Opthea.
According to their reports, current treatments are ineffective for at least half of patients short-term and the vast majority in the long-term. They only target "VEGF-A" while Opthea's 'OPT-302' molecule targets VEGF-C and VEGF-D and could therefore be used in conjunction with current treatments to enhance outcomes. The science is a million miles over my head but from a business point of view I do like the chances of selling a potential complementary product, rather than competing head on with the incumbents in the sector.
I suppose becoming a pure-play in such a potentially lucrative market has gained investor attention.
Obviously a highly speculative stock which will become worthless if trials are unsuccessful. I have a small holding. Would be interested in other members' thoughts.
http://www.asx.com.au/asx/research/company.do#!/OPT
OPT - OPTHEA: Positive news today from first human trial, jumped 10%
Last edited by DarkHorse; 26-07-2016 at 07:32 PM.
-
26-07-2016, 09:07 PM
#135
Good one.New one on me OPT and at a 1 year high.Missed your post DH.
I have done nothing for a while.The stocks i traded are a in the dumps last i looked so glad i left in the black.Only holding NRT deep in the red and getting a bit stale on it. Sa la vie. Glad some can still mine the biotech successfully. Anyone else doing well on anything in what isa depressed sector as i see it ,generally.?
Last edited by Joshuatree; 18-10-2016 at 08:19 AM.
-
26-07-2016, 10:48 PM
#136
Cheers JT. Like several health related stocks - hold PGC and LHC, and seriously looking at SDI - see http://www.capitalhmanagement.com.au...07/26/sdi-ltd/
But only hold OPT in biotech - c'est tout
Last edited by DarkHorse; 27-07-2016 at 09:53 PM.
Reason: Correction - SDI not SDA
-
31-08-2016, 01:42 PM
#137
Here's an interesting take on Australian life sciences stocks.
http://www.ndfresearch.com/the-comin...-sciences.html
-
31-08-2016, 02:00 PM
#138
Thanks macduffy. A coming boom in life sciences (Bio?)stocks ; i hope so. the thing is whats the easiest way to pick the sector taking off. I hope to start a thread about identifying and sharing a sector that takes off like the M/S did recently for great gains if one picked up on it early.
Last edited by Joshuatree; 01-09-2016 at 10:37 PM.
-
12-09-2016, 12:20 PM
#139
Two great announcements by NRT today. Im still deep in the red atm. but this looks redeeming; thinking longer term as one needs to with BIO's .DYOR
Dr James Garner presentation to Rodman & Renshaw conference-NRT.AX
FDA approves IND application for Cantrixil-NRT.AX
-
13-09-2016, 09:53 PM
#140
Originally Posted by DarkHorse
Indeed they are in early trials and unprofitable, albeit apparently sitting on $18m cash. They used to be a kind of biotech incubator with fingers in several pies. Over past year they've ditched other divisions and put sole focus on treatment for Wet AMD, the leading cause of blindness in the western world, with a potential market of $5 billion in the US and $10b worldwide. Hence the recent 'rebranding' to Opthea.
According to their reports, current treatments are ineffective for at least half of patients short-term and the vast majority in the long-term. They only target "VEGF-A" while Opthea's 'OPT-302' molecule targets VEGF-C and VEGF-D and could therefore be used in conjunction with current treatments to enhance outcomes. The science is a million miles over my head but from a business point of view I do like the chances of selling a potential complementary product, rather than competing head on with the incumbents in the sector.
I suppose becoming a pure-play in such a potentially lucrative market has gained investor attention.
Obviously a highly speculative stock which will become worthless if trials are unsuccessful. I have a small holding. Would be interested in other members' thoughts.
Does anyone else hold OPTHEA? Up a further 18% today, with latest trial results well received by "retina professionals".
http://www.marketwired.com/press-rel...xy-2157305.htm
The share price has risen steadily to have quadrupled in 12 months
Beautifully simple business model - unique but complementary therapy for the leading cause of blindness - ie not competing with existing drugs but enhancing their effectiveness.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks